Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-β signaling.
Cruz-Bermúdez A, Laza-Briviesca R, Vicente-Blanco RJ, García-Grande A, Coronado MJ, Laine-Menéndez S, Alfaro C, Sanchez JC, Franco F, Calvo V, Romero A, Martin-Acosta P, Salas C, Garcia JM, Provencio M. Cruz-Bermúdez A, et al. Among authors: vicente blanco rj. Free Radic Biol Med. 2019 Jan;130:163-173. doi: 10.1016/j.freeradbiomed.2018.10.450. Epub 2018 Nov 1. Free Radic Biol Med. 2019. PMID: 30391585 Free article.
PGC-1alpha levels correlate with survival in patients with stage III NSCLC and may define a new biomarker to metabolism-targeted therapy.
Cruz-Bermúdez A, Vicente-Blanco RJ, Laza-Briviesca R, García-Grande A, Laine-Menéndez S, Gutiérrez L, Calvo V, Romero A, Martín-Acosta P, García JM, Provencio M. Cruz-Bermúdez A, et al. Among authors: vicente blanco rj. Sci Rep. 2017 Nov 30;7(1):16661. doi: 10.1038/s41598-017-17009-6. Sci Rep. 2017. PMID: 29192176 Free PMC article.
Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition.
Cruz-Bermúdez A, Laza-Briviesca R, Vicente-Blanco RJ, García-Grande A, Coronado MJ, Laine-Menéndez S, Palacios-Zambrano S, Moreno-Villa MR, Ruiz-Valdepeñas AM, Lendinez C, Romero A, Franco F, Calvo V, Alfaro C, Acosta PM, Salas C, Garcia JM, Provencio M. Cruz-Bermúdez A, et al. Among authors: vicente blanco rj. Free Radic Biol Med. 2019 May 1;135:167-181. doi: 10.1016/j.freeradbiomed.2019.03.009. Epub 2019 Mar 14. Free Radic Biol Med. 2019. PMID: 30880247 Free article.
Spotlight on the relevance of mtDNA in cancer.
Cruz-Bermúdez A, Vicente-Blanco RJ, Gonzalez-Vioque E, Provencio M, Fernández-Moreno MÁ, Garesse R. Cruz-Bermúdez A, et al. Among authors: vicente blanco rj. Clin Transl Oncol. 2017 Apr;19(4):409-418. doi: 10.1007/s12094-016-1561-6. Epub 2016 Oct 24. Clin Transl Oncol. 2017. PMID: 27778302 Review.
Enhanced tumorigenicity by mitochondrial DNA mild mutations.
Cruz-Bermúdez A, Vallejo CG, Vicente-Blanco RJ, Gallardo ME, Fernández-Moreno MÁ, Quintanilla M, Garesse R. Cruz-Bermúdez A, et al. Among authors: vicente blanco rj. Oncotarget. 2015 May 30;6(15):13628-43. doi: 10.18632/oncotarget.3698. Oncotarget. 2015. PMID: 25909222 Free PMC article.
Correction: Enhanced tumorigenicity by mitochondrial DNA mild mutations.
Cruz-Bermúdez A, Vallejo CG, Vicente-Blanco RJ, Gallardo ME, Fernández-Moreno MÁ, Quintanilla M, Garesse R. Cruz-Bermúdez A, et al. Among authors: vicente blanco rj. Oncotarget. 2020 Mar 17;11(11):1006. doi: 10.18632/oncotarget.27522. eCollection 2020 Mar 17. Oncotarget. 2020. PMID: 32215189 Free PMC article.
Functional Characterization of Three Concomitant MtDNA LHON Mutations Shows No Synergistic Effect on Mitochondrial Activity.
Cruz-Bermúdez A, Vicente-Blanco RJ, Hernández-Sierra R, Montero M, Alvarez J, González Manrique M, Blázquez A, Martín MA, Ayuso C, Garesse R, Fernández-Moreno MA. Cruz-Bermúdez A, et al. Among authors: vicente blanco rj. PLoS One. 2016 Jan 19;11(1):e0146816. doi: 10.1371/journal.pone.0146816. eCollection 2016. PLoS One. 2016. PMID: 26784702 Free PMC article.